Genprex, Inc. (NASDAQ:GNPX) Sees Significant Growth in Short Interest

Genprex, Inc. (NASDAQ:GNPX) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 2,490,000 shares, a growth of 69.4% from the May 15th total of 1,470,000 shares. Based on an average trading volume of 4,580,000 shares, the short-interest ratio is currently 0.5 days. Approximately 9.2% of the shares of the stock are sold short.

Institutional Investors Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Geode Capital Management LLC raised its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 368.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,045 shares of the company’s stock after buying an additional 59,798 shares during the quarter. Geode Capital Management LLC owned 0.89% of Genprex worth $65,000 at the end of the most recent quarter. Institutional investors and hedge funds own 14.05% of the company’s stock.

Genprex Price Performance

Shares of NASDAQ GNPX traded up $0.01 during mid-day trading on Tuesday, reaching $0.32. 106,018 shares of the company traded hands, compared to its average volume of 3,006,941. The stock has a fifty day simple moving average of $0.28 and a 200-day simple moving average of $0.49. Genprex has a fifty-two week low of $0.22 and a fifty-two week high of $3.97.

Genprex (NASDAQ:GNPX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.56. As a group, equities research analysts forecast that Genprex will post -5.7 EPS for the current fiscal year.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.